NVO regulatory event: an FDA approval, -3.0%

On June 20, 2019, turoctocog alfa pegol — Novo Nordisk A/S (Congenital Bleeding Disorder) reached its regulatory event. The result was an FDA approval, and the stock moved -3.0% in the window around the event.